For employers
A private gut-brain programme, offered as an employee benefit.
Nerva gives every employee a guided gut-brain programme on their phone: 15 minutes a day for six weeks, with no appointments to book.
- 300,000+ people supported
- 20,000+ referring clinicians
- RCT published in the AJG1
- 4.7 / 5 from 30,000+ member reviews
What your employees receive.
A structured six-week programme of daily guided brain-gut behavioural practice, with our care team screening at intake and escalating when needed.
One 15-minute guided brain-gut session a day for six weeks: on their phone, wherever they are, with no appointment to book.
Short CBT-based lessons and diet guidance, including support for reintroducing foods they've been avoiding.
Check-ins on validated symptom measures show employees their own trajectory across the six weeks.
Our care team screens at intake, reaches out to members who go quiet, and escalates warning signs to a provider.
Every eligible employee can start on day one.
- Eligible
An eligibility list, or open access with a company link. No claims feed, no integration.
- Enrolled
Employees sign up privately in minutes. Nothing to disclose at work.
- Six weeks
A daily 15-minute session, short lessons, and symptom check-ins.
- After
Maintenance access for flare-ups; outcomes roll up into your reporting.
“Within the evidence reviewed, Nerva presented the strongest overall evidence for improving IBS symptoms.”
Peterson Health Technology InstituteVirtual Gastrointestinal Care Solutions, March 20267
Evidence you can take to committee.
81%1of participants met the primary symptom endpoint (≥50-point IBS-SSS improvement), vs 63% on active control.
Randomized controlled trial · N=244 · active control · AJG 2025 Read the research →
- Clinically significant abdominal-pain reduction, vs 35% on control1
- 71%
- Clinical studies on Nerva, indexed on our Research page
- 15+
Real-world study · presented at DDW
It moves the numbers employers watch.
In a retrospective study of over 17,000 Nerva users, completing the programme was associated with significant long-term improvements in work absenteeism, presenteeism and overall productivity.5
Private for them. Clear for you.
Nobody wants to explain gut symptoms to their manager. The reporting line is built so they never have to.
The employee
Owns their care in full
- Signs up privately from any device, with nothing to disclose at work
- Their symptoms, check-ins and progress stay theirs
- Our care team support runs member-to-Nerva, never through you
The employer
Sees the aggregate picture only
- Uptake, engagement and outcomes at the population level
- Privacy-compliant reporting on an agreed cadence
- No individual-level data. No names. Ever.
Launch without a project plan.
Nerva runs alongside your existing carrier or TPA. No claims feed, no clinical integration, and your team doesn't carry it.
Per enrolled employee. Not PEPM.
You pay for the people who actually use it, with outcome-aligned structures available. The care is software, which is what makes this pricing possible.
- Eligibility list or company link
- Communications templates included
- Aggregate reporting on a cadence
Evaluate Nerva for your population.
References
- Anderson, Ellen J.; Peters, Simone L.; Gibson, Peter R.; Halmos, Emma P. Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome. The American Journal of Gastroenterology 120(2):p 440-448, February 2025. DOI: 10.14309/ajg.0000000000002921
- Peters, S. L.; Gibson, P. R.; Halmos, E. P. App-delivered gut-directed hypnotherapy halves the long-term costs associated with managing Irritable Bowel Syndrome (IBS) symptoms and improves work productivity. Retrospective study of 17,000+ Nerva users, presented at Digestive Disease Week: IBS management costs fell from USD 1,259 to USD 502 over six months, with significant long-term improvements in work absenteeism, presenteeism and overall productivity. Retrospective completer analysis, not a controlled trial.
- Peterson Health Technology Institute. Virtual Gastrointestinal Care Solutions Assessment. March 2026.